Remote Arvinas Jobs
Upgrade to Premium and Stand Out to Recruiters
- Priority Access: Get on top of the list with a verified Match Certificate and a polished application.
- Expert Guidance: Receive personal career coaching from our dedicated Talent Team.
- Boost Your Success: Improve your chances with tailored support and feedback.
- Ongoing Assistance: Our team is here to help you every step of the way.
0 jobs found
0 jobs found
Sort by:
Relevance
Senior Manager, Planning Lead
Senior Manager, Planning Lead
4 days ago
Arvinas
72% flex
Matchscore
- Remote: United States
Associate Director, Sales Operations AnalyticsAssociate Director, Sales Operations Analytics
30+ days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
Security Operations EngineerSecurity Operations Engineer
12 days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
Executive Director, Federal AccountsExecutive Director, Federal Accounts
30+ days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
Director, Marketing, Breast CancerDirector, Marketing, Breast Cancer
30+ days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
Senior Director, US Pricing & ContractingSenior Director, US Pricing & Contracting
30+ days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
Vice President, Sales (Oncology)Vice President, Sales (Oncology)
30+ days ago
Arvinas
72% flex
Matchscore
- Full time
- Remote: United States
New!
Do you want to see hybrid jobs?
More job openings are available if you are open to hybrid remote job positions.
Include hybrid jobs
Are you looking for a Remote Arvinas Jobs?
Discover more about Arvinas ?
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Community Guidelines: http://bit.ly/ArvinasCG
